{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-23-000037","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.005980+00:00","generated_at":"2026-06-19T02:23:12.802994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B","bullets":["PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.","Net income from continuing ops $36.5M in Q4 vs loss $98.6M in Q4 2021; full-year net loss $231.8M.","Cash, equivalents and marketable securities $1.1B as of Dec 31, 2022, down from $1.3B year-end 2021.","Completed enrollment in Phase 2 RISE UP sickle cell study; on track to complete Phase 3 thalassemia enrollment by mid-2023.","Appointed Tsveta Milanova as chief commercial officer; received EU and Great Britain approvals for PYRUKYND."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-23-000037","json":"https://secwatch.observer/filing/0001439222-23-000037.json","markdown":"https://secwatch.observer/filing/0001439222-23-000037.md","text":"https://secwatch.observer/filing/0001439222-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/0001439222-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/agio-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:23:12.802994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5b9e054fd0405e414c92c7a373f9688823b1fb7","claim":"AGIOS PHARMACEUTICALS, INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for, net income Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart.","evidence_excerpt":"Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/0001439222-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended Dec. 31, 2022"},{"label":"Revenue","value":"Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for"},{"label":"Net income","value":"Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}